UBS Downgrades Nuvalent, Inc. to Hold with $124 Target

UBS analyst David Dai downgraded Nuvalent, Inc. to a hold rating, setting a $124 price target.

Written by Trueearnings · Published Jun 14, 2026, 2:01 AM EDT · Updated Jun 14, 2026, 8:00 PM EDT

Key Points

UBS analyst David Dai downgraded Nuvalent, Inc. to a hold rating on June 10, 2026, with a price target of $124.
Nuvalent shares were trading around $123.25, with a market cap of $9.75 billion and a 52-week high of $123.62.
Other analysts, including TD Cowen and Barclays, also downgraded Nuvalent to hold, aligning with UBS's sentiment.

On June 10, 2026, UBS analyst David Dai downgraded Nuvalent, Inc. (NasdaqGS: NUVL) to a hold rating, setting a price target of $124. This move aligns with several other analysts who recently adjusted their outlook on the biotech company.

Other Institutional Activity in Nuvalent, Inc.

Institutional activity around Nuvalent, Inc. has been mixed. Deerfield Management Company maintained its position with 17,248,450 shares valued at approximately $1.77 billion. FMR LLC reduced its holdings by 1,577,925 shares, ending with 9,274,959 shares worth about $950.22 million. Paradigm Biocapital Advisors LP increased its stake slightly by 55,000 shares, bringing its total to 5,324,433 shares valued at $545.49 million. BlackRock, Inc. added 19,524 shares, ending with 4,824,785 shares valued at about $494.30 million, while JPMorgan Chase & Co boosted its position by 883,098 shares, totaling 3,088,349 shares worth $298.71 million.

Nuvalent, Inc. Stock Snapshot

Shares of Nuvalent, Inc. traded near $123.25 on the NasdaqGS. The company has a market cap of approximately $9.75 billion. It is not currently profitable and thus has no meaningful P/E ratio, with a forward P/E of -29.83. The stock's 52-week range is between $71.13 and $123.62, with a 50-day moving average of $104.10 and a 200-day moving average of $98.73. Nuvalent boasts a strong liquidity position with a current ratio of 16.14 and a quick ratio of 15.89.

Recent Earnings

Nuvalent, Inc. has been focusing on developing cancer therapies but has yet to achieve profitability, reporting a net margin of 0.0% and a return on equity of -41.19%. The company is expected to release its next earnings report on August 6, 2026.

Insider Buying and Selling at Nuvalent, Inc.

Insider activity at Nuvalent shows mixed signals. On June 9, 2026, Chief Development Officer Darlene Noci sold 20,000 shares under a planned sale at an average price of $122.81. On the same day, she purchased 20,000 shares at $9.59. President and CEO James Richard Porter sold 30,000 shares at $88.53 in a planned transaction on June 8, 2026, while also buying 30,000 shares at $18.93.

Analysts Set New Price Targets

Several analysts have aligned with UBS's recent downgrade. On June 10, 2026, TD Cowen, Barclays, UBS, and Guggenheim all downgraded Nuvalent's stock to a hold rating with a $124 price target. Similarly, Wells Fargo, HC Wainwright & Co., Wedbush, and LifeSci Capital issued hold ratings with the same target on June 9, 2026. Overall, the consensus recommendation for Nuvalent is a hold, with a mean price target of $128.13 based on 16 analyst opinions.

About Nuvalent, Inc.

Nuvalent, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts. It focuses on developing therapies for cancer patients, with lead products aimed at treating resistance and adverse effects associated with existing cancer treatments. The company was founded in 2017 and is led by CEO Dr. James R. Porter.

Bottom Line

UBS's decision to downgrade Nuvalent, Inc. reflects a cautious outlook on the company's future performance. While the stock has shown strong liquidity and institutional support, the lack of profitability and recent analyst downgrades suggest a more reserved market sentiment. As a clinical-stage biotech firm, Nuvalent continues to be closely watched by investors for its potential in cancer therapy development.